161 related articles for article (PubMed ID: 38128647)
1. Proteomic Analysis Revealed the Potential Role of MAGE-D2 in the Therapeutic Targeting of Triple-Negative Breast Cancer.
Shi X; Liu C; Zheng W; Cao X; Li W; Zhang D; Zhu J; Zhang X; Chen Y
Mol Cell Proteomics; 2024 Jan; 23(1):100703. PubMed ID: 38128647
[TBL] [Abstract][Full Text] [Related]
2. Comparative proteomic profiling of triple-negative breast cancer reveals that up-regulation of RhoGDI-2 is associated to the inhibition of caspase 3 and caspase 9.
Muñiz Lino MA; Palacios-Rodríguez Y; Rodríguez-Cuevas S; Bautista-Piña V; Marchat LA; Ruíz-García E; Astudillo-de la Vega H; González-Santiago AE; Flores-Pérez A; Díaz-Chávez J; Carlos-Reyes Á; Álvarez-Sánchez E; López-Camarillo C
J Proteomics; 2014 Dec; 111():198-211. PubMed ID: 24768906
[TBL] [Abstract][Full Text] [Related]
3. Quantitative proteomics reveals stage-specific protein regulation of triple negative breast cancer.
Lin Y; Lin L; Fu F; Wang C; Hu A; Xie J; Jiang M; Wang Z; Yang L; Guo R; Yang P; Shen H
Breast Cancer Res Treat; 2021 Jan; 185(1):39-52. PubMed ID: 32920739
[TBL] [Abstract][Full Text] [Related]
4. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
5. Eugenol modulates the NOD1-NF-κB signaling pathway
Shi X; Zhang W; Bao X; Liu X; Yang M; Yin C
Front Endocrinol (Lausanne); 2023; 14():1136067. PubMed ID: 36923216
[TBL] [Abstract][Full Text] [Related]
6. Proteome profiling of triple negative breast cancer cells overexpressing NOD1 and NOD2 receptors unveils molecular signatures of malignant cell proliferation.
Velloso FJ; Campos AR; Sogayar MC; Correa RG
BMC Genomics; 2019 Feb; 20(1):152. PubMed ID: 30791886
[TBL] [Abstract][Full Text] [Related]
7. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.
Cabezón T; Gromova I; Gromov P; Serizawa R; Timmermans Wielenga V; Kroman N; Celis JE; Moreira JM
Mol Cell Proteomics; 2013 Feb; 12(2):381-94. PubMed ID: 23172894
[TBL] [Abstract][Full Text] [Related]
8. MiR-193 promotes cell proliferation and invasion by ING5/PI3K/AKT pathway of triple-negative breast cancer.
Xu JH; Zhao JX; Jiang MY; Yang LP; Sun ML; Wang HW
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3122-3129. PubMed ID: 32271430
[TBL] [Abstract][Full Text] [Related]
9. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
10. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
[TBL] [Abstract][Full Text] [Related]
11. MEX3A promotes triple negative breast cancer proliferation and migration via the PI3K/AKT signaling pathway.
Jiang S; Meng L; Chen X; Liu H; Zhang J; Chen F; Zheng J; Liu H; Wang F; Hu J; Li Z
Exp Cell Res; 2020 Oct; 395(2):112191. PubMed ID: 32738346
[TBL] [Abstract][Full Text] [Related]
12. Myricetin-induced apoptosis in triple-negative breast cancer cells through inhibition of the PI3K/Akt/mTOR pathway.
Sharma P; Khan MA; Najmi AK; Chaturvedi S; Akhtar M
Med Oncol; 2022 Oct; 39(12):248. PubMed ID: 36209343
[TBL] [Abstract][Full Text] [Related]
13. Sophoraflavanone G suppresses the progression of triple-negative breast cancer via the inactivation of EGFR-PI3K-AKT signaling.
Cheng W; Liu D; Guo M; Li H; Wang Q
Drug Dev Res; 2022 Aug; 83(5):1138-1151. PubMed ID: 35426453
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Pattern of hPTMs by Mass Spectrometry-Based Proteomics with Implications for Triple-Negative Breast Cancer.
Liu C; Xu M; Li W; Cao X; Wang Y; Chen H; Zhang T; Lu M; Xie H; Chen Y
J Proteome Res; 2024 Apr; 23(4):1495-1505. PubMed ID: 38576392
[TBL] [Abstract][Full Text] [Related]
15. Proteomic investigation on bio-corona of Au, Ag and Fe nanoparticles for the discovery of triple negative breast cancer serum protein biomarkers.
Del Pilar Chantada-Vázquez M; López AC; Vence MG; Vázquez-Estévez S; Acea-Nebril B; Calatayud DG; Jardiel T; Bravo SB; Núñez C
J Proteomics; 2020 Feb; 212():103581. PubMed ID: 31731051
[TBL] [Abstract][Full Text] [Related]
16. MAT as a promising therapeutic strategy against triple-negative breast cancer via inhibiting PI3K/AKT pathway.
Wei S; Zhang Y; Ma X; Yao Y; Zhou Q; Zhang W; Zhou C; Zhuang J
Sci Rep; 2023 Jul; 13(1):12351. PubMed ID: 37524857
[TBL] [Abstract][Full Text] [Related]
17. PRR15 deficiency facilitates malignant progression by mediating PI3K/Akt signaling and predicts clinical prognosis in triple-negative rather than non-triple-negative breast cancer.
Guo F; Ma J; Li C; Liu S; Wu W; Li C; Wang J; Wang J; Li Z; Zhai J; Sun F; Zhou Y; Guo C; Qian H; Xu B
Cell Death Dis; 2023 Apr; 14(4):272. PubMed ID: 37072408
[TBL] [Abstract][Full Text] [Related]
18. SCEL regulates switches between pro-survival and apoptosis of the TNF-α/TNFR1/NF-κB/c-FLIP axis to control lung colonization of triple negative breast cancer.
Chan SH; Kuo WH; Wang LH
J Biomed Sci; 2023 Nov; 30(1):93. PubMed ID: 38037106
[TBL] [Abstract][Full Text] [Related]
19. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
20. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
